po (' 1) 1:1 0 (1) '.n (1) Vli";:l-o.. 14 years ago (Starzl et al. 1965) , the rationale for the procedure was different from what it is today. Then, it was hoped that by short-circuiting splanchnic venous blood around the liver, glucose would be made more readily available to peripheral tissues with relief of hypoglycaemia, and that the liver would be coincidentally deglycogenated. As the content of this symposium has made clear, the consequences of portacaval shunt are far more subtle and wideranging than that simple view suggests. That first patient who had Type III glycogen storage disease is still alive almost 14 years after portacaval transposition. A patient similarly treated by Riddell et al. (1966) also survived chronically. Because our second patient died two days after portacaval transposition this procedure was abandoned. Simple portacaval shunts were used for all of the eight subsequent patients in our series, of whom seven are alive with follow-ups of eight months to more than five years (mean 60 months). Sporadic further cases summarized four years ago (Starzl et al. 1973a ) confirmed the value of portacaval shunt for palliation of these children's condition. By this time, Folkman et al. (1972) had added an important therapeutic dimension by showing how preoperative parenteral hyperalimentation would reduce the operative risk by normalizing pre-existing hep'atomegaly, acidosis and other abnormalities, including hyperlipidaemia. A final development has been the refinement of overnight feeding techniques as an alternative to portacaval shunt or as an adjuvant to the operation (see later).
The ages of our 10 patients, types of disease, and symptoms are summarized in Table 1 . Type I disease (glucose-6-phosphatase deficiency) has been the most common indication for treatment, with Type III disease (amylo-l ,6-glucosidase deficiency) being a distant second.
Metabolic effects
After portal diversion, most of the children who had pre-existing hypoglycaemia did not have relief of this problem or the relief was not complete. Thus, night" feedings usually had to be continued. Studies of plasma insulin and glucagon in several of these patients have revealed the interesting pattern shown in Fig. 1 . The flat peripheral insulin curves typical of Type I glycogen disease (Lockwood et al. 1969 ) became significantly elevated after portacaval shunt, and there were smaller increases in glucagon. The glucose tolerance curves were much the same before and after operation. Liver glycogen concentrations in all the patients later biopsied were not changed.
In spite of failure to alter the hepatic glycogen concentration, the liver size in several of our patients and those reported by others underwent a very ob-
. vious reduction as measured with liver scan planimetry. Even if obvious shrinkage did not occur, postoperative biopsies always showed a diminution in individual hepatocyte size similar to that produced in animals by portacaval shunt (Starzl et 01. 19730) . In contrast to the incomplete relief of hypoglycaemia, all components of the hyperlipidaemia which is a characteristic of the Type I disease had profound and permanent relief (Fig. 2) (1972) and in our own cases (Starzl et al. 1973a) . Correction of other metabolic defects was observed including abnormal bleeding, uric acid elevations, and abnormal calcium metabolism (Starzl et al. 1973a) .
Growth
All 10 of our patients had growth retardation before portacaval shunt. Afterwards, height increases, which in most cases had virtually ceased, have occurred at the rates listed in Table 2 , approximately 0.5 cm per month.
Quantitative measures of growth were obtained with radiographic techniques (Starzl et af. 1973a ). An example of the results is shown in Fig. 3 . Comparison of the wrist and hands in this seven-year-old stunted child before and 11 t months after operation showed the phenomenal effects of bone age doubling. In addition to the size change, mineralization occurred and the appearance of new wrist bones. Circulating somatotropin in these patients was normal. The growth spurts may have been at least partially attributable to the increased insulin distribution to the periphery mentioned earlier (see Fig. 1 ) since, in recent years, insulin has been recognized to be a major growth hormone, comparable in potency to somatotropin.
Encephalopathy and other risks
None of our patients has developed hepatic encephalopathy. The highest blood ammonia concentration recorded was 84 pg % in a child who died almost five years after portacaval shunt during an attempt at transcaval radiographic visualization of the portacaval anastomosis. This patient (no. 4) had not achieved the full expected growth after operation (Table 2) , had mild systemic hypertension, and had unexplained transient bouts of cyanosis, hyperventilation, and unconsciousness. Except for the slightly elevated blood ammonia concentration, liver function was normal.
At autopsy, the liver had macroadenomatosis. Very minor protoplasmic astrocytosis was in the brain. A finding that had not been $uspected during life was advanced right ventricular hypertrophy and dilatation. The smaller pulmonary arteries and arterioles had medial muscle hypertrophy, medial and intimal fibrosis, scattered fibrinoid necrosis, and numerous plexiform lesions. In retrospect, the patient died from a cardiopulmonary complication of the kind that has been documented in patients with Type I glycogen storage disease or other liver disease (Levine et al. 1973) .
The complication has been termed yasocoustrictive pulmonary hypertension. 
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It has been speculated that a humoral vasoconstrictive agent, which normally is completely detoxified by the liver, is responsible for the hypertrophic lesions in the pulmonary vasculature. It is conceivable although unlikely that the development of a renal art~ry stenosis in patient No.5 could have been by the same mechanism. Three of our 10 patients developed the hepatic lesions which have been termed both macroadenomatosis and nodular hyperplasia. Filling defects were noted by liver scan with some waxing and waning of size. This complication is common in patients with Type I glycogen storage disease particularly with advancing age and was recently reported in seven of eight patients who were three to 28 years old (Howell et al. 1976 ).
The value of night feedings
The failure of overnight hypoglycaemia to be relieved after portal diversion has already been mentioned. Partly for this reason, the continuous night feeding through a gastrostomy or gastric tube recently advocated by Burr et aJ. (1974) and Greene et al. (J976) has been a useful if not mandatory adjuvant in some of our cases. Glucose or amino acid mixtures have both been effective.
The night feedings have contributed to or been primarily responsible for the same kinds of growth spurts and relief of metabolic abnormalities (including hyperIipidaemia) as are ameliorated by portacaval shunt. Greene et al. (1976) have shown that systemic plasma insulin levels are more than doubled by such treatment and that glucagon is decreased, leading them to speculate that the hormone changes were responsible for the benefits. Whatever the explanation, this kind of treatment is an alternative to portal diversion as the primary treatment of children with glycogen storage disease, and even after portacaval shunt it has an additional value.
HYPERUPIDAEMIA
In the glycogen storage diseases we have been discussing, the livers are always patently abnormal because of the accumulation of glycogen, and often because of fibrosis. By contrast, the liver in homozygous Type II hyperlipoproteinaemia is morphologically normal. The reasons for the elevated serum cholesterol and the low density lipoproteins in this autosomal dominant inherited disorder are by no means understood.
Whatever its cause, the homozygous form of Type II hyperlipoproteinaemia has a shockingly poor prognosis even with attemps at rigid medical therapy. Lipid-rich deposits are laid down in widely separated ~upaficial and deep parts of the body (Fig. 4) . and the same accumulations cause advanced aortic stenosis and coronary artery disease which are responsible for death before the age of20 years in the usual case.
In an effort to reduce the serum cholesterol and lipoprotein levels, we performed an end-to-side portacaval shunt on March I, 1973, in an II-year-old girl with homozygous Type II hyperlipoproteinaemia that was refractory to medical treatment (Starzl et al. 1973b) . The patient had suffered a myocardial infarction about two months previously. After surgery, the serum cholesterol values fell from about 800 mg/IOO ml to levels that were consistently below 400 rog/IOO rol (Fig. 5) . Unsightly xanthomas began to resOib from visible subcutaneous and tendinous locations. At the same time, attacks of the pre-existing angina pectoris became less frequent and finally stopped. From cardiac catheterization 16 months after the end-to-side portacaval shunt was performed, there was good evidence that aortic stenosis had been reversed with a diminution of the aortic valve gradient from 56 to 10 mmHg (Starzl et al. 1974a) . The coronary arteries were also thought to be less diseased than before, although three stenoses were still present. More than It years later, the girl died suddenly while coming home from school. The autopsy findings led to the conclusion that death was caused by an acute cardiac arrhythmia related to the residual coronary artery disease or to the earlier myocardial infarction (Starzl et al. 1974b Table 3 .
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The portacaval shunt was widely patent. The liver, which weighed 618 g, was grossly normal, and microscopically it was unchanged from the biopsy specimen that was obtained six months postoperatively. On light and electron microscopy, the most prominent findings were shrinkage of the hepatocyte size, depletion of rough endoplasmic reticulum, and the accumulation of intracytoplasmic lipid deposits. These changes are typical of the portaprival condition in all species, as we mentioned earlier (Starzl et 01., this volume, pp. /11-129). Hepatic function had not been changed by portacaval shunt as judged by standard liver function tests.
We have performed a portacaval shunt on two more patients with the same diagnosis (Cases 2 and 3, Table 3 ). Patient 2 is a seven-year-old girl who had preoperative serum cholesterol values that averaged 997 ±47 (S.D.) mg/IOO ml while she was on a very low cholesterol diet. Six months after the shunt, the cholesterol level measured in the same laboratory was 600 mg/lOO ml (a 40 % reduction), despite a relaxation of the diet, and now the cholesterol concentrations are about 450-500 mg/lOO ml (Table 3 ). This child also had aortic stenosis and angina pectoris. Because of persistence of her cardiac disease, she was treated with aortic and mitral valve replacement plus double coronary artery by-pass two years after portacaval shunt. She is well.
Our third patient has had a reduction in serum cholesterol from 1000 mg/IOO ml to 600-650 mg! 100 ml in the 21 months since the operation (Table 3) . Although the cholesterol falls were less striking than in our first two patients, visible xanthomas are slowly resorbing and the patient is asymptomatic.
The changes in peripheral insulin content in these patients have been analogous to those in patients treated for glycogen storage disease, but starting with preoperatively normal values. Postoperatively, systemic venous insulin and glucagon values were both increased, especially the former (Fig. 6 ). None of our three patients with hyperlipidaemia has had any signs of hepatic encephalopathy. Nevertheless, this clinical application for hyperlipidaemia, as in the patients with glycogen storage disease, accepts a 'trade-off' of distinctly suboptimal conditions of liver perfusion in return for metabolic improvements that are derived from these suboptimal conditions. Realization of this fact has encouraged us to maintain a conservative and discriminating attitude about the recommendation of portacaval shunt for either kind of inborn error. The freedom from encephalopathy in our cases may be partly due to the fact that we have treated children only.
Other reports
Shortly after portacaval shunt was first proposed for the treatment of hyperlipidaemia, a plea was made by Ahrens (1974) that all such patients be carefully studied and faithfully reported to a central registry. Knowledge has been acquired in this way about more than 30 patients. More importantly, formal reports have appeared in the literature on nine of these cases in addition to our own three (Krogh & Wickens 1974; Stein et al. 1975; Russell et al. 1976 ; Cywes et al. 1976; Farriaux et al. 1976; Weglicki et al. 1977 Our experiments have suggested that the main reason for decreased hepatic cholesterol synthesis is deprivation of the liver of insulin (Starzl et al. 1975) . Eaton (1976) has recently proposed that the changes in glucagon metabolism may be important.
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Discussion
Smith-Laing: 00 you attribute the fall in lipids in the hyperlipidaemic patients to a general decrease in metabolic processes in the liver? Have you looked at any other synthetic process, such as the rate of synthesis of albumin, to see if it is correlated with the fall in lipids?
Starzl: The answer to your first question is yes. The answer to the second question is no,' we haven't. I think the fall in cholesterol concentration is mainly due to a decrease in hepatic cholesterol synthesis, which in dogs falls to about one-seventh after a shunt (Starzl et 01. 1975) . Ahrens (1974) has a contributory (not alternative) explanation: he suggests that the loss of bile acids (by removal of the portal enterohepatic circulation) creates an obligatory drain of the cholesterol pool.
Smith-Laing: Beckelbaum and his colleagues tried complete biliary diversion without a shunt in three patients with homozygous hypercholesterolaemia and the synthesis of cholesterol kept up with any amount of bile acids that could be drained (Beckelbaum et 01. 1977) , so presumably it is a combination of causes.
Starzl: Yes. Buchwald et al. (1974) also showed, using an ileal by-pass in which the loss of bile acids increased by several-fold, that the rate of cholesterol synthesis increased to match the loss. So the chief mechanism seems to be the loss of cholesterol synthesis .
McIntyre: I don't believe that. There is no convincing evidence that it is high cholesterol synthesis in the liver which increases serum cholesterol in these patients. They have increased amounts of low density lipoproteins (LOL). These are not normally produced in the liver; they result from catabolism of plasma very low density lipoprotein (VLOL) (Sigurdsson et 01.1975) . It seems unnecessary to invoke changes 'in hepatic cholesterol synthesis as an explanation. Reduced cholesterol synthesis in the liver after a shunt could be a consequence of the fall in plasma LOL, because the cholesterol in LDL must presumably be cleared via the liver, and excreted in bile either as cholesterol or as bile acids. It seems likely that the transfer of LO L cholesterol to the liver and its accumulation there might inhibit further synthesis.
Bloom: What happens to the high density lipoprotein (HOL) level? Storz!: Portal diversion has a general antilipidaemic effect in man (affecting all the lipid moieties). In animals we found that only cholesterol falls after shunt.
Leffert: What is the evidence that the liver doesn't produce LDL directly?
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McIntyre:
The studies by the Bethesda group (Eisenberg et al. 1973) suggest that the turnover of the p-apoprotein of VLOL accounts for all the turnover of LOL apoprotein. Furthermore, if you look for lipoprotein particles in liver by electron microscopy you see VLOL but not LOL particles (Marsh 1971) . Some people think that some LOL is produced in the liver, without good evidence.
Starzl: Hepatic cholesterol or LOL synthesis (or both) have been studied in dogs (Starzl et al. 1975) , in rats (Edwards et al. 1976; James et al. 1977) , in pigs (Chase & Morris 1976; and in a human with Type 11 hyperlipidaemia (Bilheimer et al. 1975) . The cholesterol or LOL synthesis was reduced in all these investigations. When both cholesterol and LOL synthesis were measured, as was done for example in Bilheimer's patient, they fell together.
McIntyre: It has been claimed that LDL is secreted directly from the liver in patients homozygous for Type II hypercholesterolaemia (Soutar et al. 1977) . The evidence is indirect. If the suggestion is correct we must invoke a special mechanism for LDL production in these patients.
Starzl: You may be correct about a special mechanism, but several of the reports J cited did not question the role of the liver in LOL synthesis. I was not aware that the connection between cholesterol and LOL metabolism was in question in experimental animals or humans.
McIntyre: The work by Goldstein & Brown (1975) suggests that LOL is removed from plasma by various cells, including fibroblasts, which have specific LOL receptors. If, as in homozygous Type II hypercholesterolaemia, there are no receptors for LOL on the cells, one would expect high cholesterol levels in plasma. This is an excellent explanation for the hypercholesterolaemia and extremely good evidence must be produced in support of another mechanism involving abnormalities of LOL secretion in these patients.
Leffert: Of the hormones we have been talking about, the group in J. W. Porter's laboratory (Ness et al. 1973; Nepokroeff et al. 1974) showed that insulin, glucagon, L-triiodothyronine and hydrocortisone regulate HMG-coA (P-hydroxy-p-methylglutaryl coenzyme A) reductase.
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protein /3, from VLDL. But it has been claimed that the fatty acid composition of the cholesteryl esters in LDL is different from that found in VLDL (Goodman 1965 ). This could be explained by a transfer of cholesteryl ester to L 0 L from HDL, either directly or indirectly via VL DL, during the turnover process. Lecithin cholesterol acyl transferase (LeAT) certainly appears to be responsible for the synthesis of plasma cholesteryl esters. Th 1t enzyme uses unsaturated fatty acids rather than saturated fatty acids.
Why is cholesterol synthesized in the liver? It has always been assumed that the liver makes cholesterol to secrete into plasma; but this doesn't make sense, because almost all tissues are capable of synthesizing cholesterol. It can't be excreted other than by the liver, so the main flow of cholesterol has to be centripetal for the purposes of excretion. I think we must assume that the liver makes cholesterol for bile acid production, and that synthesis is controlled and regulated by the input of cholesterol from other tissues via the blood .
Star=l: What is the reason for the fall in cholesterol LDL and VLDL in these patients?
AI cIntyre: I don't know. It is an extremely exciting observation but I don't think an easy answer comes out of it.
Starzl: May I go to a different topic? As I described in my paper (p. 323), there has been a fall in plasma cholesterol after portacaval shunt in almost every patient with hyperlipidaemia (about 30 in all throughout the world) except three in whom the shunts clotted and in which the tied-off central portal vein was re-vascularized through collaterals. Are there clotting disorders in these patients? At least one patient (in Europe) had a stroke, a child, a week before a shunt was planned. There has been some suspicion of a hypercoagulable state which has contributed to the shunt closure in 10 % of the cases and even to the other vascular complications.
Folkman: I have been intrigued by an apparent difference between the coagulation system in children with Type I glycogen storage disease and children with hyperIipidaemia Type II. The glycogen storage disease patients often have prolonged bleeding times (up to 30-40 minutes), but their platelet counts are normal. They may require hospitalization for prolonged nosebleeds. However, as their high serum lipid levels are brought down to the normal range by intravenous glucose or by intragastric feedings of glucose, the bleeding time returns to normal (FOlkman et of. 1972) . It is thought that the high serum lipids in these patients prevent normal platelet agglutination.
By contrast, children with hyperlipidaemia Type II, who also have high lipid levels, have a normal bleeding time, and in some of these children, the bleeding time is very short.
Perhaps this difference contributes to the higher rates of shunt closure in , · · ;r .,
328 DISCUSSION the hyperlipidaemia Type II children who had portacaval shunts than in the glycogen storage disease patients who had shunts.
Weinbren: From a pathological viewpoint, there is a characteristic type of atheroma in hyperlipidaemic patients. It is found in the first 4 em of the ascending aorta and may involve the coronary ostia. The lesion in the coronary artery in the girl who eventually died was not the usual one. It might have been a superimposed thrombus, far down the coronary artery. The others seemed to wax and wane with treatment by plasmapheresis. Therefore on the angiogram if one finds a lesion along the coronary artery, that may be the one to treat with by-pass, but if it is at the ostium, it may recede.
Starzl: Yes. These lesions in two of our patients were in the ascending aorta and in one there was a big atheroma acting almost like a ball valve, and presumably compromising the coronary ostia. But in these two patients, including one who eventually had a triple coronary artery by-pass, there was also peripheral arterial disease.
In all the early cases of portal diversion for hyperlipidaemia, the patients had homozygous disease. There are also heterozygotes but with high levels of 600-700 mg/100 ml cholesterol. One such patient was recently reported from Harvard in which coronary artery by-passes were combined with portacaval shunt with good results (Weglicki et al. 1977) . Extension from the homozygous disease to the heterozygous condition may presage a more frontal assault on traditional premature coronary artery disease which involves peripheral vessels .
Weinbren: We have seen heterozygotes who have lesions in the first part of the ascending aorta which may be different from general atheroma in an old patient. But full documentation on this point is not yet available.
Folkman: Why does the glycogen storage disease patient with a very high cholesterol level never develop arterial disease?
M cJntyre: The cholesterol is in different particles; it is presumably not predominantly in low density lipoproteins, as it is in Type II hypercholesterolaemia, but rather in VLDL and chylomicrons. The patients whom Dr Starzl is talking about don't have high levels of triglycerides.
Starzl: The relation of the atherosclerosis in hyperlipidaemia to conventional atherosclerotic disease will be interesting to define, particularly if the lesions can be reversed. Small & Shipley (1974) looked at the question of the factors that would make it possible for atherosclerosis to be cleanly reversed, from a physicochemical point of view. The conclusions were somewhat discouraging. Although reversal would seem to be possible in terms of lipid removal, a lot of residual fibrotic changes cannot be expected to go away. I would therefore tend to be much more aggressive than I was with our child who died of coronary artery complications. If there was a serious cardiovascular complication, J would combine portal diversion with traditional cardiac surgery approaches.
McIntyre: If people start to do shunt:> in heterozygote:;, we shall soon know all the answers about portal deprivation; they would be excellent people to study! Star:::l: Yes, and clearly they will respond as well as the homozygotes in terms of serum lipid lowering. .. 
